Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that ...

A combination mRNA cancer vaccine from BioNTech and Regeneron may be one step closer to actualization based on initial Phase 2 results unveiled Tuesday. The mRNA-based vaccine, BNT111, in combination ...

BioNTech SE will showcase data from its oncology pipeline at the AACR Annual Meeting in Chicago from April 25-30, 2025. The presentations will highlight advancements in mRNA cancer immunotherapies, ...

MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at ...

BioNTech is buying fellow German firm CureVac for approximately $1.25 billion as the COVID-19 vaccine maker moves to expand into cancer treatments. For each CureVac share they own, investors will get ...

BioNTech is flush with Covid-19 vaccine revenue and it’s putting some of that money to work by acquiring rights to a therapy in the hot area of antibody drug conjugates, or ADCs. It’s the second such ...

BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic. Also Read: FDA ...

Add Yahoo as a preferred source to see more of our stories on Google. The Biontech logo can be seen on one of the company's warehouse buildings in Mainz. Sebastian Gollnow/dpa German vaccine ...

The FDA has imposed a partial clinical hold on the Phase I trial of an antibody-drug conjugate (ADC) cancer therapy candidate being co-developed by BioNTech and MedLink Therapeutics, three days after ...

BioNTech slashed its annual guidance by as much as 1 billion euros. It also reduced spending in response to lowered demand for first vaccine doses as well as boosters it developed with Pfizer. However ...

(Reuters) - COVID-19 vaccine maker BioNTech's cancer drug candidate BNT111 showed significant improvement in the response rate in patients with advanced melanoma during a Phase 2 trial, the German ...